Limitations Of FDA's Adverse Event Reporting System Highlighted By Vioxx
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck's withdrawal of Vioxx illustrates the shortcomings of adverse event reporting systems for detecting common events